{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:21Z","timestamp":1786988121186,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Carboplatin\/pegylated liposomal doxorubicin\/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinical use. Among these adverse events, acquired amegakaryocytic thrombocytopenia is a rare but often potentially life-threatening adverse effect, and is intolerant to multiple treatment approaches. We report, for the first time, the successful treatment using avatrombopag combined with cyclosporine in one case of carboplatin\/pegylated liposomal doxorubicin\/bevacizumab-induced acquired amegakaryocytic thrombocytopenia, which was refractory or intolerant to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, androgen, and even thrombopoietin receptor receptor agonist eltrombopag and herombopag. To date, this case manifests as normal platelet counts that are independent of transfusion. Our findings suggest that this combination is a potential and valuable alternative in acquired amegakaryocytic thrombocytopenia.<\/jats:p>","DOI":"10.3389\/fonc.2024.1253230","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T04:25:51Z","timestamp":1707452751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful avatrombopag combined with cyclosporine treatment for carboplatin\/pegylated liposomal doxorubicin\/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Weikang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18235","article-title":"Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia","volume":"198","author":"Roeser","year":"2022","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.56875\/2589-0646.1063","article-title":"Acquired amegakaryocytic thrombocytopenic purpura: A review of therapeutic options","volume":"16","author":"Hussain","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20510","article-title":"Acquired amegakaryocytic thrombocytopenic purpura","volume":"81","author":"Agarwal","year":"2006","journal-title":"Am J Hematol"},{"key":"B5","article-title":"Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE)","volume":"8","author":"Cela","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-011-0656-x","article-title":"Good response to cyclosporin in a child with acquired thrombocytopenic purpura","volume":"79","author":"Jain","year":"2012","journal-title":"Indian J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.5190","article-title":"Thrombocytopenia and anemia with anti-c-Mpl antibodies effectively treated with cyclosporine in a patient with rheumatoid arthritis and chronic renal failure","volume":"55","author":"Hashimoto","year":"2016","journal-title":"Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.4081\/hr.2016.6680","article-title":"Invasive thymoma with pure red cell aplasia and amegakaryocytic thrombocytopenia","volume":"8","author":"Onuki","year":"2016","journal-title":"Hematol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04053-y","article-title":"Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody","volume":"99","author":"Iyama","year":"2020","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7812\/TPP\/19.203","article-title":"Acquired amegakaryocytic thrombocytopenia misdiagnosed as immune thrombocytopenia: A\u00a0case report","volume":"24","author":"Roy","year":"2020","journal-title":"Perm J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.20047","article-title":"Acquired amegakaryocytic thrombocytopenia after durvalumab administration","volume":"61","author":"Suyama","year":"2021","journal-title":"J Clin Exp Hematop"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.2012140","article-title":"Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant","volume":"33","author":"Tian","year":"2022","journal-title":"Platelets"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795884","article-title":"Case report: successful avatrombopag treatment for two cases of anti-PD-1 antibody-induced acquired amegakaryocytic thrombocytopenia","volume":"12","author":"Tu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: A review in thrombocytopenia","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0149","article-title":"Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia","volume":"12","author":"Gay","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.09.001","article-title":"Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation","volume":"12","author":"Simkins","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1253230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T04:25:54Z","timestamp":1707452754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1253230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":16,"alternative-id":["10.3389\/fonc.2024.1253230"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1253230","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"article-number":"1253230"}}